Different childhood symptoms led to a diagnosis of GAMT deficiency, an inherited creatine production disorder

Since the previous research note · Earlier expectation not tested

Track continuity

Since the previous research note: What can creatine-deficient mice reveal about brain development?

Previous expectation: A better-characterized mouse model might help develop treatments that protect neurological development in children if metabolic changes could be linked to developmental outcomes and translated to people.

What this study adds: The March 2025 source adds two human diagnostic and treatment histories and a compilation of reported clinical cases, documenting different changes in seizures, urinary metabolism and everyday functioning. It does not test mouse-to-human prediction or treatment before symptoms appear.

---

What changed in this study

One child had recurring seizures and difficulty learning. The other had developmental delays, hyperactivity, and trouble concentrating, without reported clinical seizures. Their outward difficulties differed, but investigations pointed toward the same rare disorder of creatine production.

A paper published March 15, 2025, describes these two children treated at Xiangya Hospital, Central South University, in China. It combines a retrospective account of their diagnosis and follow-up with a literature compilation covering 136 reported cases, including these two patients.

The histories show how a metabolic explanation can emerge from symptoms that initially offer few distinctive clues. They also give families a concrete way to understand follow-up: changes in seizures, a urine measurement, and everyday learning describe different aspects of a child’s health.

A missing step in creatine production

GAMT is short for guanidinoacetate methyltransferase, an enzyme involved in making creatine. It helps convert guanidinoacetate, abbreviated GAA, into creatine. When the enzyme does not work properly, GAA accumulates and creatine synthesis is impaired.

Creatine helps meet the energy needs of tissues such as the brain. Disrupting its supply can therefore have neurological consequences, including developmental difficulties, seizures, movement problems, and behavioral symptoms. The metabolic defect involves both a shortage of the product and a buildup of its precursor.

GAMT deficiency belongs to a group of inherited creatine deficiency syndromes. Another form affects a different synthesis enzyme, AGAT, while a third affects creatine transport. Identifying which process is disrupted matters because a low creatine signal alone does not identify the underlying defect.

How the diagnostic clues came together

The girl, described at age 6 years and 11 months, had experienced staring episodes since a little after age 3. Her eyes sometimes turned to one side during the episodes, which lasted several seconds. Seizures continued despite treatment with several antiseizure medicines. Developmental testing had also documented difficulties, particularly in language and related skills.

The boy, described at age 7 years and 6 months, had shown developmental concerns at a routine examination at 9 months. Hyperactivity and poor attention became apparent by age 4. Later assessments documented intellectual disability and attention-deficit hyperactivity disorder. Neither child had distinctive facial features or obvious abnormalities of muscle strength and tone on examination.

Magnetic resonance spectroscopy, or MRS, supplied a shared clue. This technique measures chemical signals in the brain, complementing the structural pictures obtained with conventional MRI. Both children had a reduced creatine peak. That finding supported a problem with brain creatine availability, even though their clinical presentations differed.

In the boy, urine testing added evidence about the specific metabolic step. His GAA-to-creatinine ratio was 1,004.93 mmol/mol creatinine, above the laboratory’s reported reference range of 10–280. Creatinine here is the substance used to express the urinary ratio; it is distinct from the creatine being investigated in the brain.

Family genetic testing then found two different GAMT variants in each child, with one inherited from each parent. This arrangement is called compound heterozygosity. The observations addressed complementary questions: spectroscopy indicated reduced brain creatine, the boy’s urine test identified excess precursor, and sequencing supplied inherited-variant evidence. The authors interpreted these findings together with the clinical histories to diagnose GAMT deficiency.

Follow-up captured several kinds of change

For the girl, creatine was added after diagnosis to a treatment course that included levetiracetam, sodium valproate, and perampanel. The authors report that, after three months of creatine supplementation, she went more than two years without obvious clinical seizures.

Her latest four-hour electroencephalogram, or EEG, nevertheless still showed abnormal electrical discharges. Hyperventilation during the assessment provoked an absence seizure, a brief interruption of awareness. The distinction matters: a substantial reduction in seizures noticed in daily life did not amount to complete disappearance of seizure activity. At her last follow-up, she was in third grade, could manage daily self-care, and cooperated in conversation, but continued to have poor school performance and difficulty concentrating.

The boy’s clearest numerical follow-up result came from urine testing. Four months after starting creatine, his GAA-to-creatinine ratio had fallen to 399.35 mmol/mol creatinine. That was a marked decline from the initial measurement, while still exceeding the reported upper reference value of 280. No clinical seizures were reported, including before treatment, so their absence cannot establish a preventive effect. At his last follow-up, he was in fifth grade and could manage self-care, but learning difficulties, poor attention, and emotional excitability remained.

These findings illustrate why neurological recovery cannot be read from a single result. A urinary ratio describes metabolism; an EEG records electrical activity; school performance and daily functioning describe abilities in a child’s life. Improvement in one does not establish improvement in all the others. The persistent difficulties also do not prove that further gains are impossible. These histories document the children’s reported course over the available follow-up, without establishing a fixed limit on future development.

What the 136 reported cases add

The authors’ compilation included 21 cases reported in China, counting their two patients, and 115 reported elsewhere. They selected genetically diagnosed cases with sufficiently complete clinical information. Every included patient had reported developmental delay or intellectual disability.

Other features varied. Seizures were recorded in 91 of 136 cases, or 66.9%; motor disorders in 46, or 33.8%; and behavioral problems in 50, or 36.8%. These overlapping categories show the range of presentations in the selected literature. They are not population estimates or a diagnostic checklist with known accuracy. Published case histories can differ in which symptoms were assessed, documented, and considered worth reporting.

Creatine treatment was reported in 102 of the 136 cases, or 75%. That percentage describes treatment exposure, not treatment success. The authors summarize improvements in seizures and motor problems across the treated case literature, with less substantial cognitive improvement, but the compilation does not provide a uniform response measure from which to calculate a dependable success rate.

Treatment attribution and genetic uncertainty remain open

A change observed after treatment is useful evidence, but assigning its cause requires more. In the girl’s case, concurrent antiseizure therapy complicates any estimate of creatine’s independent contribution. Because the compilation brings together previously reported cases rather than participants followed under one common prospective protocol, direct comparisons are limited. There was no controlled treatment comparison or uniform prospective assessment of outcomes.

Those gaps leave the size of the treatment effect, the best regimen, and the influence of treatment timing unresolved. Estimating the benefit of earlier treatment would require comparable developmental assessments and careful accounting for how children differed before treatment began. These two histories do not test intervention before symptoms appeared.

Genetic interpretation has a separate uncertainty. A clinically supported diagnosis does not make every proposed variant mechanism experimentally proven.

Three of the four variants were described as previously unlisted in the mutation database consulted by the authors. Computational predictions suggested possible effects, including disruption of RNA processing, but the paper explicitly calls for further validation of their pathogenic effects. Functional experiments would need to establish what these variants actually do to RNA or enzyme activity. Their identification alone cannot reliably predict a child’s eventual abilities or treatment response.

What this could change

The practical opportunity is earlier access to care directed at an underlying metabolic cause. If clinicians recognize that unexplained developmental difficulties can warrant metabolic investigation even without obvious seizures, more affected children could reach a diagnosis through the combined use of biochemical testing, brain spectroscopy, and genetics.

If that earlier recognition leads to timely specialist treatment with meaningful benefit, children could experience fewer seizures and less disruption to daily life, with a reduced burden on caregivers. Protecting neurological development remains an important possibility to establish beyond these cases. From the March 2025 perspective, the immediate contribution is a clearer account of how children with different symptoms can reach targeted care—and how follow-up can describe the benefits they actually experience.

Key Sources

• Primary source: [Two cases of creatine deficiency syndrome caused by GAMT gene mutations and literature review].
  DOI or Journal Page · Review or Meta-Analysis · 2025-03-15